Salmonella presents a global public health concern. Central to Salmonella pathogenicity is an ability to subvert host defence mechanisms through bacterial effectors that target key host proteins implicated in restricting infection. Thus, to gain insight into host-pathogen interactions governing Salmonella infection, a thorough understanding of host defence mechanisms is needed. To tackle this, we performed an in vivo genome-wide ENU mutagenesis screen to uncover novel host defence proteins. Through this screen we identified an uncharacterised protein, which we name CYRI1 (CYFIP-related RAC1 Interacting protein 1) that serves as a Salmonella resistance factor. We show that CYRI1 binds to the small GTPase RAC1 through a conserved domain present in CYFIP proteins, which are known RAC1 effectors that stimulate actin polymerisation. However, unlike CYFIP proteins, CYRI1 negatively regulates RAC1-driven actin cytoskeleton remodelling, thereby attenuating processes such as phagocytosis and cell migration. This, in turn, enables CYRI1 to counteract Salmonella at various stages of infection, including bacterial entry into epithelial cells, internalisation into myeloid-derived phagocytes as well as phagocyte-mediated bacterial dissemination. Together, this outlines a novel host defence mechanism that is crucial for determining bacterial fate.
pedigree exhibited increased susceptibility to S. Typhimurium infection ( Fig. 1 a, b) .
In vivo imaging with bioluminescent Salmonella also revealed progressive bacterial load increase in Ity15 mutants (Ity15 m/m ) starting as early as three days post infection ( Fig. 1 c) . Additionally, infected Ity15 m/m mice displayed significantly higher bacterial load in the spleen and liver compared to littermate controls (Fig. 1 d) . Consistently, serum pro-inflammatory (TNFα and IL-6) and anti-inflammatory (IL-10) cytokines were significantly higher in mutant mice at day 5 post-infection (supplementary Fig. 1 a). Ity15 m/m mice also presented multiple abscesses in the spleen and liver, with lesions being more diffuse in the Ity15 m/m spleen and the white pulp showing marked lymphocytolysis. The Ity15 m/m liver also presented more parenchymal necrosis with the presence of frequent fibrin thrombi in the microvasculature when compared to controls ( Supplementary Fig. 1 b) . Overall, these pathological changes are indicative of the presence of an overwhelming septicaemia in Ity15 m/m mice with induction of disseminated intravascular coagulation.
To pinpoint the causative mutation underlying the Ity15 m/m phenotype, we outcrossed the G1 male to DBA/2J females to generate F1 and intercrossed F1 mice to produce F2 progeny. We performed genome-wide linkage analysis in 24 F2 (9 Salmonellasusceptible and 15 Salmonella-resistant) mice using polymorphic Single Nucleotide Polymorphisms (SNPs) between 129S1 and DBA/2J. This revealed a single linkage peak on chromosome 15 with an LOD score of 4.54 between markers rs3677062 and rs13482628, delineating an interval of 4.4 Mb ( Supplementary Fig. 2 a) . F2 mice homozygous for the 129S1 mutant allele (Ity15 m/m ) at the peak marker on chromosome 15 succumbed to infection by day 8 compared to heterozygous (Ity15 +/m ) and wild type (Ity15 +/+ ) mice ( Supplementary Fig. 2 b) . Interestingly, exome sequencing performed in two susceptible F2 animals identified four ENU-induced homozygous Single Nucleotide Variants (SNVs). Importantly, one of the identified SNVs was found in Cyri1 (Fam49b), an uncharacterised protein-coding gene, that maps to the critical interval on chromosome 15. The mutation within Cyri1 consisted of a T to A substitution within the splice donor site of exon 9 resulting in exon 9 skipping and causing a frameshift and a premature stop codon within exon 10 (p.N212GfsX9) ( Fig. 2 a and Supplementary Fig. 2 c) . Indeed, biochemical analysis of spleen and liver tissues revealed that the splicing mutation abrogates CYRI1 protein expression in Ity15 m/m mice (Fig. 2 b) .
To further validate Cyri1 as the causative gene underlying susceptibility in Ity15 m/m mice, we performed allelic complementation in which heterozygous (Ity15 +/m ) mice were crossed to mice heterozygous for a knockout (KO) allele at Cyri1 (Cyri1 +/-). We next assessed survival in F1 animals upon S. Typhimurium infection to ascertain susceptibility ( Supplementary Fig. 2 d) . Interestingly, we observed a lack of complementation with Ity15 m /Cyri1mice being as susceptible as Ity15 m/m mice ( Fig.   2 c), confirming that the observed Cyri1 mutation is responsible for Salmonella susceptibility in Ity15 m/m mice. This identifies Cyri1 as a Salmonella resistance gene with loss of CYRI1 expression resulting in enhanced Salmonella dissemination and septic shock.
CYRI1 is a CYFIP-related RAC1 effector
Given the uncharacterised nature of CYRI1, we next explored its potential cellular functions. Primary structural analysis revealed that CYRI1 shares 80 % sequence identity with FAM49A, a closely related uncharacterised protein, within a single domain, Domain of Unknown Function 1394 (DUF1394), which is found in two other proteins in the human proteome: CYFIP1 and CYFIP2 ( Supplementary Fig. 3 a) .
CYFIP proteins are part of the WRC and are integral in relaying information from active RAC1 to the ARP2/3 complex, by directly binding to RAC1 19 . This raised the possibility that CYRI1 might also bind to active RAC1. Indeed, in vitro biochemical assays demonstrated that CYRI1 associates with RAC1 ( Fig. 3 a) . The CYRI1-RAC1 interaction was also observed in cells, as evident by duolink in situ proximity ligation assays using antibodies against endogenous RAC1 and endogenous or exogenous CYRI1 ( Fig. 3 b, c) . Moreover, GST pulldown experiments using purified GST-RAC1 loaded with either GDP or GTPγS to mimic inactive and active RAC1, respectively, revealed that CYRI1 binds preferentially to active RAC1 ( Fig. 3 d) . Consistently, endogenous RAC1 from HEK293T lysates pre-treated with GTPγS displayed enhanced binding to GST-CYRI1 compared to endogenous RAC1 from GDP pretreated lysates ( Fig. 3 
e, f).
Despite a weak sequence homology of ~ 20 %, the HHpred 30 predicted CYRI1 structure suggests that CYRI1 shares significant structural similarity with the CYFIP1 DUF1394 domain (score= 493.83, e-value=1.5e-58) ( Supplementary Fig. 3 b) . A reported WRC structure indicated the presence of two RAC1 binding sites, cysteine 179 (C179) and arginine 190 (R190), within the CYFIP1 DUF1394 domain, which abrogate RAC1 binding when mutated to R and aspartic acid (D), respectively 21 . In CYRI1, proline 150 (P150) and R161 correspond to CYFIP1 C179 and R190, respectively ( Supplementary Fig. 3 c, d ). We therefore generated P150R and R161D single and double CYRI1 mutants to assess their RAC1 binding ability. To eliminate any potential non-specific binding due to dimerization between the mutants and endogenous CYRI1 or FAM49A, we expressed these mutants in a CYRI1/FAM49A double KO HEK293T cell line (HEK293T CYRI1/FAM49A KO) and performed GST pulldown using GTPγS-loaded purified GST-RAC1. Consistent with the high conservation between CYRI1 R161 and CYFIP1 R190, the R161D mutation significantly reduced RAC1 binding. In contrast, the CYRI1 P150R mutation had no effect on CYRI1-RAC1 interaction ( Fig. 3 g, h) . However, the P150R/R161D CYRI1 double mutant displayed a greater reduction in RAC1 binding compared to the R161D mutant alone, suggesting that while non essential, P150 also contributes to RAC1 interaction ( Fig. 3 g, h) . Together, this demonstrates that CYRI1 is evolutionary related to CYFIP proteins and can similarly interact with RAC1.
CYRI1 negatively regulates RAC1 signalling
Both the structural homology to CYFIP proteins and its ability to bind to RAC1 hinted at a potential role of CYRI1 in regulating RAC1-driven actin cytoskeletal modulation.
To test this, we generated CYRI1 KO HeLa cells and assessed their morphology ( Fig. 4 a) . CYRI1 KO cells exhibited a round, unpolarised and flattened pancake-like morphology with extensive membrane ruffling and increased cellular spread and circularity compared to parental or control KO HeLa cells ( Fig. 4 b-e). These morphological changes were also accompanied by extensive actin cytoskeletal rearrangements, as indicated by phalloidin, ACTIN and RAC1 immunofluorescence staining ( Fig. 4 f and Supplementary Fig. 4 a) .
Intriguingly, HeLa cells expressing the RAC1 activating mutant, RAC1 P29S displayed a round and flattened morphology similar to that observed upon CYRI1 deletion ( Supplementary Fig. 4 b-d), which is consistent with previous observations linking the pancake-like morphology to RAC1 hyperactivation 31 . This suggested that the morphological changes associated with CYRI1 KO might be due to increased RAC1 activation, leading to intensified cytoskeletal dynamics. Indeed, increased active RAC1 levels were observed in CYRI1 KO cells ( Fig. 4 g) . Additionally, CYRI1 KO HeLa cells displayed enhanced actin polymerisation, as measured by an increased filamentous (F)-actin to monomeric (G)-actin ratio when compared to parental or control KO HeLa cells ( Fig. 4 h) . Together, this identifies CYRI1 as a negative regulator of RAC1-driven actin cytoskeletal remodelling.
CYRI1 restricts Salmonella entry and dissemination by modulating cytoskeletal processes
RAC1 activation and subsequent actin polymerisation is central for Salmonella internalisation into non-phagocytic enterocytes 24 . We therefore hypothesised that CYRI1 might impede bacterial entry. To investigate this, we assessed bacterial entry in parental, control KO or CYRI1 KO HeLa cells following Salmonella infection as a model of bacterial internalisation into non-phagocytic enterocytes in the gut. Indeed, CYRI1 deletion resulted in increased Salmonella internalisation relative to parental and control KO cells ( Supplementary Fig. 5 a, b), indicating that CYRI1 inhibits actin cytoskeletal rearrangements required for bacterial entry. RAC1-driven actin cytoskeleton remodelling also plays a major role in mediating phagocytosis 32 and cell motility 33 . This is particularly relevant in myeloid-derived phagocytes, such as macrophages and neutrophils, which can foster bacterial replication and dissemination in vivo 4, 6, 7, 34, 35 . We therefore evaluated the role of In addition to utilising phagocytes as a replicative niche, Salmonella also stimulate phagocyte migration to aid dissemination to secondary tissues, such as the spleen and liver 4, 6, 7 . RAC1 is known to guide neutrophil trafficking between the bone marrow and the blood as well as cell migration within tissues 36 . To further investigate whether the phenotype observed in infected Cyri1 -/flox mice is due to deregulation of RAC1 signalling, we also examined the impact of CYRI1 deletion on neutrophil motility in a 3D collagen matrix as a model of their movement in vivo. such that their directional persistence was reduced, suggesting that neutrophils were switching to a more random mode of migration in the absence of CYRI1, which is consistent with RAC1 hyperactivation 37 . These changes in the regulation of neutrophil migration upon CYRI1 KO could help explain the enhanced Salmonella dissemination observed in Cyri1 -/flox mice, thus implicating CYRI1 in restricting this process.
Discussion
Bacterial pathogens and host cells are in a constant "arms race" for survival. While Salmonella evolved various means to hijack key host proteins implicated in defence against infection 38 , host cells also devised multiple mechanisms to combat infection 39 . Given the high disease burden associated with Salmonella infection 1 and the complexity of host-pathogen interactions governing Salmonella pathogenicity, it is crucial to gain a better understanding of the different strategies employed by pathogens as well as host cells in the course of an infection. In an attempt to tackle this, we performed an in vivo genome-wide ENU mutagenesis recessive screen aimed at identifying novel host Salmonella resistance proteins. Here, we describe the role of CYRI1, a novel cytoskeletal regulator, in counteracting Salmonella infection. In particular, we show that through binding to the small GTPase RAC1 and negatively regulating its activity and downstream actin polymerisation, CYRI1
restricts Salmonella at multiple stages of infection. This highlights an intricate mechanism by which one host protein is able to modulate host resistance through targeting Salmonella at critical stages of its infection cycle, such as bacterial entry to different cell types and bacterial dissemination ( Fig. 6 ).
CYRI1 is a previously uncharacterised highly conserved protein, which according to the human protein atlas 40 is ubiquitously expressed. Using in silico structural analysis, we show that CYRI1 and FAM49A are evolutionary related to CYFIP proteins. Of particular interest was the observation that while harbouring very little sequence homology overall, CYRI1 and CYFIP proteins are highly homologous within the DUF1394 domain, both on a primary and tertiary structural level.
Importantly, our biochemical data also demonstrate a similar RAC1 binding platform within CYRI1 and CYFIP proteins, identifying the DUF1394 domain as a putative RAC1 binding motif.
RAC1-downstream signalling is implicated in both promoting and inhibiting bacterial infection 41 . Here, we demonstrate that modulation of cellular processes dependent on RAC1-driven actin cytoskeleton remodelling in the haematopoietic compartment is crucial for determining bacterial fate. We show that loss of CYRI1 leads to increased bacterial phagocytosis in macrophages and enhanced cellular migration in neutrophils. Increased levels of tissue macrophages, neutrophils and dendritic cells are a hallmark of Salmonella infection 42 . In fact, macrophages are amongst the most highly enriched phagocytes in PP and MLNs, followed by neutrophils during oral Remodelling of the host cytoskeletal network is a key feature of many enteropathogenic bacteria. As such, cytoskeletal regulators are amongst the most commonly exploited host proteins by pathogenic bacteria 16, 24 . This raises the possibility that Salmonella might regulate CYRI1 cellular functions upon infection, particularly given its role in counteracting Salmonella-mediated cytoskeletal rearrangements. Indeed, evidence from the literature seems to suggest that CYRI1 is a Salmonella targeted host protein. For instance, it has been shown that CYRI1 mRNA levels are differentially reduced upon Salmonella infection 43 . Additionally, using quantitative mass spectrometry, we recently identified global host ubiquitinome changes following S. Typhimurium infection, highlighting the ability of Salmonella to modulate host signalling cascades via regulating ubiquitylation of host proteins.
Interestingly, CYRI1 was among the identified proteins and displayed increased ubiquitylation on lysine (K) 74 upon proteasomal inhibition, suggesting that CYRI1 is targeted for proteasomal degradation upon infection 44 . This, together with our in vivo infection data help outline a novel host-pathogen signalling axis involving CYRI1 that is crucial for determining bacterial fate.
In addition to bacterial infection, deregulation of RAC1 signalling is detrimental for normal cellular functioning and is implicated in a wide range of human diseases, including cancer, cardiovascular diseases and neurodegenerative disorders 41 . Thus, identifying CYRI1 as a RAC1 signalling inhibitor is likely to play a role in cellular contexts beyond bacterial infection. This calls for additional studies in the future to examine the role of CYRI1 under physiological and other pathological conditions.
Methods
Antibodies. Antibodies utilised in this study are outlined in Supplementary Methods Table 1 . ENU mutagenesis. Generation 0 (G0) 129S1 males were mutagenized with a single intraperitoneal injection of 150 mg per kg of body weight of N-ethyl-N-nitrosourea (ENU). G0 males were outcrossed to 129X1 females to create G1 progeny that were subsequently outcrossed to 129X1 females. Resulting G2 females were backcrossed to parental G1 males to produce the G3 mice that were assessed for susceptibility to Salmonella infection. The G1 male from the Ity15 pedigree was outcrossed to a DBA/2J female to generate F1 offspring. F1 mice were intercrossed to generate F2 offspring, which were then used for mapping. Crossing Ity15 +/m with Cyri1 +/generated mice used for the allelic complementation assay. The Ity15 m/m allele was then transferred to 129X1 background by serial backcrossing (n= 9).
In vivo Salmonella infection and bioluminescence live imaging. Mice were
injected intravenously in the caudal vein with 5,000 Colony Forming Units (CFUs) of S. Typhimurium (strain Keller). Mice were euthanized on days 3, 4 or 5 post infection to harvest spleen and liver as previously described 45 Constructs. Details of plasmids used in this study are summarised in Supplementary Methods Table 2 . 
Biochemical analysis of actin polymerisation. Monomeric actin (G-actin) and
filamentous actin (F-actin) were extracted from cell lysates using the G-actin/F-actin in vivo assay Biochem Kit (Cytoskeleton, Inc., BK037) according to manufacturer's instructions. Levels of G-actin and F-actin were determined by western blotting using anti-ACTIN antibody provided with the kit. Western blot scans were imported into imageJ and band intensities were quantified as detailed below. Actin polymerisation was calculated as the ratio of F-actin band intensities to G-actin band intensities. As a control, an F-actin enhancing solution, provided in the kit, was used.
Western blot analysis. Samples were mixed with the appropriate volume of 2x
Laemmli sample buffer (Biorad, 1610737) and resolved on 4-20 % (Biorad, 4561094, 4561043, 451045 and 4561046) or 12 % self-cast gels. Prestained protein ladder (BioFroxx, 1123YL500) was run alongside the samples for protein size reference.
Proteins were transferred onto Immobolin PVDF membranes (Millipore, IPFL00010).
Western blotting was performed using antibodies listed in Supplementary Methods Table 1, 
Bone marrow-derived cells isolation: Femurs and tibias were collected aseptically.
After removing most of the muscle and fat, the epiphyses were cut and bones were placed into modified PCR tubes individually hung by the hinge into a 1.5 ml Eppendorf containing 300 µl of sterile PBS. The bone marrow was flushed by short centrifugation at 5,000 rpm for 10 seconds or alternatively using a 25G needle. Red blood cells were lysed with RBC lysis buffer (Sigma Aldrich, 11814389001) incubating for 4 minutes at RT. Cells were pelleted and resuspended in 1 ml sterile PBS or cRPMI (10% FBS, 1% penicillin-streptomycin) media. To generate Bone Marrow-Derived Macrophages (BMDMs), cells were plated in a 10 cm petri dishes supplemented with 30 % M-CSF every two days for a total of six days at 37 °C and 5 % CO 2 .
In vitro Salmonella infection. Parental, control KO and CYRI1 KO HeLa cells were plated on coverslips in 6-well plates for 24 hours after which cells were infected with S. Typhimurium (strain SL1344) at a multiplicity of infection (MOI) of 8. After addition of bacteria, cells were incubated for 30 minutes at 37 °C and 5 % CO 2 , before addition of 100 µg/ml gentamicin to kill extracellular bacteria. To assess bacterial entry, cells were washed twice with PBS and prepared for immunofluorescence as outlined above. To visualise intracellular bacteria anti-Salmonella antibody (CSA-1;
KPL 01-91-99-MG) was utilised. Images were captured using confocal microscopy and analysed in Cell profiler 2.2.0 (rev 9969f42) to calculate the number of bacteria per cell.
Salmonella phagocytosis and replication assays. Ex vivo phagocytosis and
replication in BMDMs were assessed using an adapted gentamicin protection assay protocol 50 . BMDMs were isolated and cultured as described above. BMDMs were seeded in a 24-well plate on 12 mm diameter glass coverslips at 2-2. 
